Blood test to personalize treatment for painful diabetic neuropathy
Laboratory Developed Test (LDT) to Support Clinical Evaluation of a Drug for Painful Diabetic Neuropathy
This project will create a blood test to find people with painful diabetic neuropathy who are most likely to respond to a new drug that targets a chemokine receptor.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Plumeria Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Plainsboro, UNITED STATES) |
| Project ID | NIH-11065310 on NIH RePORTER |
What this research studies
You would give a blood sample so researchers can measure levels of a specific chemokine receptor gene linked to nerve pain. They will analyze stored blood samples and clinical data from earlier trials of a drug that blocks that receptor to see which genetic profiles corresponded with better responses. The team will develop and validate a laboratory-developed test (LDT) in the lab using those samples. The test could be used in future clinical trials to match people with painful diabetic neuropathy to the drug.
Who could benefit from this research
Good fit: Ideal participants are people with painful diabetic neuropathy who have ongoing neuropathic pain, are willing to provide a blood sample, and may consider joining future clinical trials.
Not a fit: People without diabetic neuropathy, whose pain is not neuropathic, or who are unwilling to provide blood samples are unlikely to benefit from this project.
Why it matters
Potential benefit: If successful, the test could help match patients with painful diabetic neuropathy to a medication more likely to reduce their nerve pain.
How similar studies have performed: Previous clinical trials of the same receptor-blocking drug showed acceptable safety but lacked patient genetic selection, so using a biomarker to match patients is a relatively new but promising approach.
Where this research is happening
Plainsboro, UNITED STATES
- Plumeria Therapeutics, INC. — Plainsboro, United States (Active)
Researchers
- Principal investigator: Richardson, Thomas P — Plumeria Therapeutics, INC.
- Study coordinator: Richardson, Thomas P
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.